Abstract | OBJECTIVE: METHODS: Fifty eight patients with ACS were randomly separated into three groups. 20 patients in group A were given routine therapy, 20 patients in group B were given routine therapy with oral fluvastatin 40 mg once daily for 1 week and 18 patients in group C received routine therapy with oral fluvastatin 80 mg once daily for 1 week. 20 patients with stable coronary heart disease served controls. The serum levels of hs-CRP and TNFalpha before and after therapy were measured with immunoturbidimetric assay and ELISA method. RESULTS: (1) The serum levels of hs-CRP and TNFalpha in the patients with ACS were significantly higher than those in the control group (P < 0.05). (2) The serum levels of hs-CRP and TNFalpha significantly lowered after one week of therapy in the two fluvastatin treated groups (P < 0.01 in all), especially in the 80 mg fluvastatin group, while no significant difference was observed before and after treatment in the routine therapy group. (3) The serum levels of hs-CRP and TNFalpha had a significant positive correlation in the patients with ACS (r = 0.70, P < 0.01), but no relationship were observed between TC, TG, LDL-C, or HDL-C and hs-CRP or TNFalpha by Pearson correlation analysis. CONCLUSIONS: The serum levels of inflammatory factors including CRP and TNFalpha are increased in patients with ACS and early fluvastatin intervention may decease dose-dependently the serum levels of hs-CRP and TNFalpha. The anti-inflammatory effect of fluvastatin may be beyond that of lipid lowering. Early intensive fluvastatin treatment may yield more significant benefits in the patients with ACS.
|
Authors | Jun Yang, Xiang-ping Li, Shui-ping Zhao, Jiang Li, Jing-dong Li, Xiao-ming Xie, Jun Peng |
Journal | Zhonghua nei ke za zhi
(Zhonghua Nei Ke Za Zhi)
Vol. 44
Issue 3
Pg. 184-7
(Mar 2005)
ISSN: 0578-1426 [Print] China |
PMID | 15840256
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anticholesteremic Agents
- Fatty Acids, Monounsaturated
- Indoles
- Lipids
- Tumor Necrosis Factor-alpha
- Fluvastatin
- C-Reactive Protein
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anticholesteremic Agents
(administration & dosage)
- C-Reactive Protein
(metabolism)
- Coronary Disease
(blood, drug therapy)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Fatty Acids, Monounsaturated
(administration & dosage)
- Female
- Fluvastatin
- Humans
- Indoles
(administration & dosage)
- Inflammation
(blood)
- Lipids
(blood)
- Male
- Middle Aged
- Tumor Necrosis Factor-alpha
(metabolism)
|